Skip to content

The Role of Deep Cerebral Vein Variation in Patients With Angiographic Negative Subarachnoid Hemorrhage

The Role of Deep Cerebral Vein Variation in Patients With Angiographic Negative Subarachnoid Hemorrhage

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04941846
Enrollment
296
Registered
2021-06-28
Start date
2013-01-31
Completion date
2023-01-31
Last updated
2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subarachnoid Hemorrhage, Aneurysmal

Brief summary

The incidence of Rosenthal basilar vein (BVR) variants (deep venous drainage variants) was relatively increased in patients with AN-SAH compared with patients with aneurysms. However, the inclusion criteria for AN-SAH patients in these studies were different. Some studies have investigated both PAN-SAH and NPAN-SAH, while some studies have only investigated PAN-SAH patients. However, we believe that NPAN-SAH may be the bleeding caused by non-BVR variation. Although previous studies did not find any association between NPAN-SAH and BVR variants, the results in their study were different, which may be due to the limited number of cases.

Interventions

DRUGnimodipine and euvolemia

administered nimodipine to prevent vasospasm, and euvolemia was maintained via intravenous hydration

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years

Inclusion criteria

Patients with negative subarachnoid hemorrhage diagnosed by DSA

Exclusion criteria

1. In patients with aneurysms, external ventricular drainage (EVD) alone or decompression craniotomy alone or conservative treatment was performed 2. Have a history of trauma or prior brain injury (stroke, cerebral hemorrhage, etc., with associated chronic changes on CT) 3. Patients with loss of imaging data and severe comorditions prior to onset of SAH

Design outcomes

Primary

MeasureTime frameDescription
favorable or poor outcome1 yearpoor outcome (mRS 2-6) or favorable outcome (mRS 0-1).

Countries

China

Contacts

Primary ContactJianmin Zhang, MD
zjm135@zju.edu.cn+86 13805722695
Backup ContactSheng Chen, MD
saintchan@zju.edu.cn+86 13645814323

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026